Sourcing comparator drugs for clinical trials is a complex process, especially for branded drugs, and in many cases the selection process to find the best sourcing partner falls short of expectations. An analysis has shown that around 30-55% of comparator drugs are left unused at the end of the trial. This is due to issues such as disruptions in the supply chain, unexpected delays, incomplete paperwork, stock-out situations and regulatory hurdles. Mark Walls at Verastem Inc., Rahul Sodhi of Beroe Inc. and Dr Mihai Bragaru of Durbin PLC reflect on comparator sourcing.
https://international-pharma.com/wp-content/uploads/2015/10/Comparator-sourcing.pdf
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
Comparator Sourcing – An Analytical Approach to Find Best Suited Sourcing Strategies
